[Inhaled bronchodilators and mucolytic agents in cystic fibrosis].
Poor clearance of airway secretions contributes to the pulmonary disease in cystic fibrosis (CF). Bronchodilator therapy might benefit in CF, but the efficacy is controversial. Effects of mucolytic agents have not been demonstrated conclusively. Only, efficacy of recombinant human deoxyribonuclease (rhDNase) is established with a rapid onset of benefit.
Le Roux
P
P
Centre de ressources et de compétence dans la mucoviscidose, département de pédiatrie, groupe hospitalier, 55 bis, rue Gustave-Flaubert, 76600 Le Havre, France. pleroux@ch-havre.fr
Le Luyer
B
B
D000280:Administration, Inhalation; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000188:drug therapy*; D003851:Deoxyribonucleases / Q000627:therapeutic use; D005100:Expectorants / Q000627:therapeutic use*; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use
D001993:Bronchodilator Agents; D005100:Expectorants; D011994:Recombinant Proteins; D003851:Deoxyribonucleases